SG178106A1 - Antiviral compounds and methods of making and using thereof - Google Patents

Antiviral compounds and methods of making and using thereof Download PDF

Info

Publication number
SG178106A1
SG178106A1 SG2012005450A SG2012005450A SG178106A1 SG 178106 A1 SG178106 A1 SG 178106A1 SG 2012005450 A SG2012005450 A SG 2012005450A SG 2012005450 A SG2012005450 A SG 2012005450A SG 178106 A1 SG178106 A1 SG 178106A1
Authority
SG
Singapore
Prior art keywords
compound
branched
linear
nitro
group
Prior art date
Application number
SG2012005450A
Other languages
English (en)
Inventor
Yitsun Richard Kao
Dan Yang
Kwokyung Yeun
Original Assignee
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versitech Ltd filed Critical Versitech Ltd
Publication of SG178106A1 publication Critical patent/SG178106A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG2012005450A 2009-08-05 2010-08-05 Antiviral compounds and methods of making and using thereof SG178106A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23143109P 2009-08-05 2009-08-05
PCT/CN2010/001187 WO2011015037A1 (en) 2009-08-05 2010-08-05 Antiviral compounds and methods of making and using there of cross reference to related applications

Publications (1)

Publication Number Publication Date
SG178106A1 true SG178106A1 (en) 2012-03-29

Family

ID=43543887

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012005450A SG178106A1 (en) 2009-08-05 2010-08-05 Antiviral compounds and methods of making and using thereof

Country Status (13)

Country Link
EP (1) EP2462138B1 (enExample)
JP (1) JP2013501008A (enExample)
KR (1) KR20120092567A (enExample)
CN (1) CN102596946B (enExample)
AU (1) AU2010281265A1 (enExample)
BR (1) BR112012002331A2 (enExample)
CA (1) CA2770140A1 (enExample)
IL (1) IL217745A0 (enExample)
IN (1) IN2012DN01254A (enExample)
MX (1) MX2012001504A (enExample)
RU (1) RU2012104214A (enExample)
SG (1) SG178106A1 (enExample)
WO (1) WO2011015037A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011147198A1 (en) * 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treatment of proliferative diseases
ES2533068T3 (es) * 2010-09-08 2015-04-07 Bristol-Myers Squibb Company Nuevos análogos de piperazina como antivirales de influenza de amplio espectro
JP2013542201A (ja) * 2010-09-28 2013-11-21 ブリストル−マイヤーズ スクイブ カンパニー 広域スペクトルのインフルエンザ抗ウイルス剤としての置換されたヘテロアリール基を有する新規ピペラジン類似体
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
WO2012134967A2 (en) * 2011-03-25 2012-10-04 Bristol-Myers Squibb Company Three-dimensional structure of hin1 nucleoprotein in complex with antiviral compounds
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
CN102432555A (zh) * 2011-09-09 2012-05-02 中国科学院广州生物医药与健康研究院 1,2,3-三氮唑-4(5)羧酰胺类化合物及其应用
KR20140131971A (ko) 2012-03-13 2014-11-14 레스피버트 리미티드 신규 약학 제제
CN104540810B (zh) * 2012-05-18 2017-01-18 维洛诺瓦流感公司 具有抗病毒活性的甲硫酮化合物
US9676734B2 (en) 2012-05-18 2017-06-13 Vironova Influenza Ab Compounds and methods
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JO3279B1 (ar) 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
EP3027608B1 (en) * 2013-07-30 2019-02-20 Janssen Sciences Ireland Unlimited Company Substituted pyridine-piperazinyl analogues as rsv antiviral compounds
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
CN107056762B (zh) * 2016-12-22 2020-08-28 四川百利药业有限责任公司 一种用作抗流感病毒的双羰基类似物
JP2020506192A (ja) * 2017-02-02 2020-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. インフルエンザウイルスを阻害するためのピペラジン誘導体
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3103385A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI765323B (zh) * 2019-08-22 2022-05-21 大陸商四川海思科製藥有限公司 抗流感病毒化合物及其製備方法和用途
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
WO2021204924A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Compounds for use in the treatment of hypercytokinemia
WO2021204923A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Antiviral agents
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
ES3028915T3 (en) 2021-04-16 2025-06-20 Gilead Sciences Inc Methods of preparing carbanucleosides using amides
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117150A (ja) * 1991-10-25 1993-05-14 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
KR200293242Y1 (ko) * 2002-04-18 2002-11-01 전이범 산소 절단기호스
DE10236564A1 (de) * 2002-08-08 2004-05-19 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von papaverinartigem Vasodilatator und pharmazeutische Zusammensetzung
CN101142198B (zh) * 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
EP2462138A1 (en) 2012-06-13
RU2012104214A (ru) 2013-09-10
CN102596946B (zh) 2015-06-17
IL217745A0 (en) 2012-03-29
MX2012001504A (es) 2012-06-01
BR112012002331A2 (pt) 2019-09-24
AU2010281265A1 (en) 2012-03-22
EP2462138A4 (en) 2013-01-23
CN102596946A (zh) 2012-07-18
IN2012DN01254A (enExample) 2015-05-15
KR20120092567A (ko) 2012-08-21
AU2010281265A2 (en) 2012-04-05
EP2462138B1 (en) 2014-09-24
WO2011015037A1 (en) 2011-02-10
JP2013501008A (ja) 2013-01-10
CA2770140A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
EP2462138B1 (en) Antiviral compounds and methods of making
US9212177B2 (en) Antiviral compounds and methods of making and using thereof
CN104334563B (zh) 7‑氧代‑噻唑并吡啶碳酸衍生物和它们在治疗、改善或预防病毒疾病中的用途
CN104507481B (zh) 用于治疗、改善或预防病毒疾病的7‑氧代‑4,7‑二氢‑吡唑并[1,5‑a]嘧啶衍生物
WO2011147199A1 (en) Compounds and methods for treating viral infections
US20130325429A1 (en) Compounds and Methods for the Treatment of Viral Infections
CN104619699A (zh) 二羟基嘧啶碳酸衍生物以及它们在治疗、改善或预防病毒疾病中的用途
CN103958521B (zh) 嘧啶-4-酮衍生物及其在治疗、减轻或预防病毒疾病中的用途
WO2017060470A1 (en) Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
JP2011502998A (ja) ウイルス感染の治療および予防
TW201446774A (zh) 抗病毒化合物
JP2009179589A (ja) 抗ウイルス剤
WO2014092514A1 (ko) 신규한 화합물, 이의 약학적으로 허용가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
CN118063386B (zh) (e)-n-[(1h-吲唑-7-基)甲基]-3-芳基丙烯酰胺衍生物的制备及其应用
EP1844776B1 (en) Agent for prevention/treatment of disease caused by acyclovir-resistant herpesvirus
CN108129486A (zh) 嘧啶酮衍生物及其用途
CN113979936A (zh) 2-芳脲基-n-[3-(4-吗啉基)丙基]烟酰胺类化合物及其应用
CN114057635A (zh) 2-芳脲基-n-[2-(2-甲氧基苯氧基)乙基]烟酰胺类化合物及其应用
CN113979935A (zh) 2-芳脲基-n-(4-氟苄基)烟酰胺类化合物及其应用
CN117700396A (zh) 含吡啶-苯环结构的杂芳基嘧啶类衍生物及其制备方法和用途
CN116903590A (zh) 一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN113214219A (zh) 一种奥司他韦氨基衍生物及其制备方法与应用